PRESS RELEASE

BC Platforms to support Pfizer in cardiovascular disease research

BC Platforms, a provider of genomic data management and analytics, has announces that Pfizer Finland will be using its technology solutions and research platform, including, to study data in cardiovascular diseases.

The services will be used to analyse anonymised data from Turku University Hospital and other health care providers to generate real world evidence in atrial fibrillation patients.  Microsoft will provide the cloud infrastructure for indexing and accessing the information globally through the Microsoft Azure cloud platform.

Jaakko Parkkinen, country medical director at Pfizer commented, ‘Cardiovascular diseases are the leading cause of global mortality in the world and the incidence is rising due to an aging population.  The diseases are complex and therefore we need data to fully understand and provide the best treatment outcomes for patients. We believe that combining our expertise in the treatment of cardiovascular diseases with BC Platforms’ advanced genomic and clinical data management solutions, we can gather and analyse important real-world evidence to generate optimal patient outcomes.’

Samu Kurki, lead scientist at BC Platforms commented: ‘Pfizer is one of the leaders in providing treatment solutions for patients suffering from cardiovascular diseases and we are delighted that they have chosen to collaborate with us to support the generation of real-world evidence in this space to better understand the complexities of the disease. These types of projects are ideal for leveraging data from innovative healthcare systems to support clinical research and outcomes.’

Pfizer and BC Platforms are both part of the FinnGen project, which is one of the largest global research projects aiming to improve human health through genetic research. The collaborative nature of the project is exceptional and all the partners are working closely together to ensure appropriate transparency, data security and ownership. Finland is leading the field in this space due to its combination of unique genetic heritage, decades of population-wide medical registry data, progressive government legislation and cutting-edge genomics technologies.

Other tags: 
Feature

Robert Roe reports on developments in AI that are helping to shape the future of high performance computing technology at the International Supercomputing Conference

Feature

James Reinders is a parallel programming and HPC expert with more than 27 years’ experience working for Intel until his retirement in 2017. In this article Reinders gives his take on the use of roofline estimation as a tool for code optimisation in HPC

Feature

Sophia Ktori concludes her two-part series exploring the use of laboratory informatics software in regulated industries.

Feature

As storage technology adapts to changing HPC workloads, Robert Roe looks at the technologies that could help to enhance performance and accessibility of
storage in HPC